| Literature DB >> 30659677 |
Frank E van Boven1, Lidia R Arends2,3, Gert-Jan Braunstahl4,5, Roy Gerth van Wijk1.
Abstract
Asthma affects three hundred million people worldwide. The effectiveness of house dust mite allergen control for asthma treatment is debatable. One aspect that has been little discussed in existing meta-analyses is the possible role of environmental strategies. Here, we reintroduce the previously defined strategies for mite allergen control and discuss their importance to the debate on clinical effectiveness. The strategy of concurrent bedroom interventions is related to the combined use of a priori defined interventions, while the strategy of exposure-based control relates to the treatment of relevant textiles after assessing exposure. The air purification strategy aims to purify the human breathing zone of airborne allergens. In Western European patient practice, the use of these strategies differs. A post hoc study of the dominant Cochrane review by Gøtzsche and Johansen (Cochrane Database of Systematic Reviews, 2008, Art. No: CD001187) appears to indicate that a majority of the underlying trials reported on the strategy of concurrent bedroom interventions, which were mainly executed in a minimal manner. Some trials have reported on the air purification strategy and may potentially alter the debate on effectiveness. No trial has reported on the strategy of exposure-based control. We therefore hypothesize that the absence of evidence for the effectiveness of mite allergen control for asthma treatment applies to the strategy of concurrent bedroom interventions. The evidence-based effectiveness of the exposure-based control strategy appears to be undetermined. The results of our post hoc reanalysis urge that future meta-analyses of mite allergen control should a priori define the environmental strategy under study. Future trials of mite allergen control are warranted to test the exposure-based strategy as well as the sparsely tested strategy of air purification.Entities:
Keywords: allergens; asthma; environment; house dust mite allergen control; strategy of avoidance
Mesh:
Substances:
Year: 2019 PMID: 30659677 PMCID: PMC6850033 DOI: 10.1111/cea.13340
Source DB: PubMed Journal: Clin Exp Allergy ISSN: 0954-7894 Impact factor: 5.018
Environmental strategy categories of the trials studied by Gøtzsche and Johansen37
| Trial | Author | Year | Strategy | Barriers | Remark |
|---|---|---|---|---|---|
| 1 | Antoniceli | 1991 | Air purification | NA | |
| 2 | Bahir | 1997 | Concurrent bedroom | 1 | |
| 3 | Burr | 1980A | Concurrent bedroom | 1 | |
| 4 | Burr | 1980B | Concurrent bedroom | 1 | |
| 5 | Carswell | 1996 | Concurrent bedroom | 3 | |
| 6 | Chang | 1996 | Concurrent bedroom | 1 | |
| 7 | Chen | 1996 | Concurrent bedroom | 1 | |
| 8 | Cinti | 1996 | Concurrent bedroom | 1 | Strategy extracted from description by Gøtzsche and Johansen |
| 9 | Cloosterman | 1999 | Concurrent bedroom | 2 | |
| 10 | De_Vries | 2007 | Concurrent bedroom | 1 | |
| 11 | Dharmage | 2006 | Concurrent bedroom | 1 | |
| 12 | Dieteman | 1993 | Concurrent bedroom | 1 | |
| 13 | Dorward | 1988 | Concurrent bedroom | 1 | |
| 14 | Ehnert | 1992 | Concurrent bedroom | 2 | |
| 15 | Fang | 2001 | Concurrent bedroom | 1 | |
| 16 | Geller‐Bernst | 1995 | Concurrent bedroom | 1 | |
| 17 | Halken | 2003 | Concurrent bedroom | 1 | |
| 18 | Htut | 2001 | Concurrent bedroom | 1 | |
| 19 | Huss | 1992 | Concurrent bedroom | 1 | |
| 20 | Kroidl | 1998 | Concurrent bedroom | 1 | |
| 21 | Maesen | 1977 | Air purification | NA | |
| 22 | Marks | 1994 | Concurrent bedroom | 2 | |
| 23 | Reiser | 1990 | Concurrent bedroom | 1 | |
| 24 | Rijssenbeek | 2002 | Concurrent bedroom | 3 | |
| 25 | Sette | 1994 | Concurrent bedroom | 1 | |
| 26 | Shapiro | 1999 | Concurrent bedroom | 2 | |
| 27 | Sheikh | 2002 | Concurrent bedroom | 1 | |
| 28 | Thiam | 1999 | Concurrent bedroom | 2 | |
| 29 | Van_der_Heide | 1997A | Concurrent bedroom | 1 | |
| 30 | Verrall | 1988 | Air purification | NA | |
| 31 | Walshaw | 1986 | Concurrent bedroom | 1 | |
| 32 | Warburton | 1994 | Air purification | NA | |
| 33 | Warner | 1993 | Air purification | NA | |
| 34 | Woodcock | 2003 | Concurrent bedroom | 1 | |
| 35 | Wright | 2009 | Concurrent bedroom | 1 | |
| 36 | Zwemer | 1973 | Air purification | NA |
Standardized mean differences in asthma symptom scores related to environmental strategy in the meta‐analysis by Gøtzsche and Johansen37
| Strategy | SMD | 95% CI | Patients ( |
|
|
|---|---|---|---|---|---|
| Sojourn high altitude | NA | NA | NA | NA | NA |
| Total avoidance | NA | NA | NA | NA | NA |
| Exposure‐based | NA | NA | NA | NA | NA |
| Concurrent bedroom | −0.07 | −0.35 to 0.21 | 1415 | 0.62 | 68% |
| 1 barrier | −0.03 | −0.37 to 0.32 | 1169 | 0.87 | 54% |
| 2‐3 barriers | −0.25 | −0.89 to 0.40 | 246 | 0.43 | 91% |
| Air purification | −0.53 | −1.35 to 0.30 | 70 | 0.19 | 68% |
| Mixed strategies | −0.13 | −0.40 to 0.15 | 1485 | 0.35 | 72% |
| Gøtzsche & Johansen | −0.06 | −0.16 to 0.05 | 1485 | 0.29 | 68% |
Standardized mean differences as calculated by Gøtzsche and Johansen37 with a fixed‐effect model.
Standardized mean differences in FEV1 related to environmental strategy in the meta‐analysis by Gøtzsche and Johansen37
| Strategy | SMD | 95% CI | Patients ( |
|
|
|---|---|---|---|---|---|
| Sojourn high altitude | NA | NA | NA | NA | NA |
| Total avoidance | NA | NA | NA | NA | NA |
| Exposure‐based | NA | NA | NA | NA | NA |
| Concurrent bedroom | 0.14 | −0.02 to 0.29 | 633 | 0.08 | 0% |
| 1 barrier | 0.11 | −0.11 to 0.33 | 332 | 0.32 | 0% |
| 2‐3 barriers | 0.17 | −0.06 to 0.40 | 301 | 0.15 | 28% |
| Air purification | 0.07 | −0.53 to 0.68 | 42 | 0.81 | 0% |
| Mixed strategies | 0.13 | −0.02 to 0.29 | 675 | 0.09 | 0% |
| Gøtzsche & Johansen | 0.13 | −0.02 to 0.28 | 675 | 0.09 | 0% |
Standardized mean differences as calculated by Gøtzsche and Johansen37 with a fixed‐effect model.
Standardized mean differences in PC20 related to environmental strategy in the meta‐analysis by Gøtzsche and Johansen37
| Strategy | SMD | 95% CI | Patients ( |
|
|
|---|---|---|---|---|---|
| Sojourn high altitude | NA | NA | NA | NA | NA |
| Total avoidance | NA | NA | NA | NA | NA |
| Exposure‐based | NA | NA | NA | NA | NA |
| Concurrent bedroom | 0.05 | −0.09 to 0.20 | 475 | 0.45 | 0% |
| 1 barrier | 0.05 | −0.20 to 0.30 | 254 | 0.68 | 0% |
| 2‐3 barriers | 0.05 | −0.21 to 0.32 | 221 | 0.69 | 0% |
| Air purification | −0.12 | −1.05 to 0.80 | 18 | 0.80 | 0% |
| Mixed strategies | 0.05 | −0.13 to 0.22 | 493 | 0.61 | 0% |
| Gøtzsche & Johansen | 0.05 | −0.13 to 0.22 | 493 | 0.61 | 0% |
Standardized mean differences as calculated by Gøtzsche and Johansen37 with a fixed‐effect model.
Standardized mean differences in medication usage related to environmental strategy in the meta‐analysis by Gøtzsche and Johansen37
| Strategy | SMD | 95% CI | Patients ( |
|
|
|---|---|---|---|---|---|
| Sojourn high altitude | NA | NA | NA | NA | NA |
| Total avoidance | NA | NA | NA | NA | NA |
| Exposure‐based | NA | NA | NA | NA | NA |
| Concurrent bedroom | −0.04 | −0.16 to 0.08 | 1043 | 0.49 | 0% |
| 1 barrier | −0.04 | −0.16 to 0.08 | 1043 | 0.49 | 0% |
| 2‐3 barriers | NA | NA | NA | NA | NA |
| Air purification | −0.17 | −0.64 to 0.29 | 72 | 0.46 | 0% |
| Mixed strategies | −0.05 | −0.17 to 0.07 | 1115 | 0.39 | 0% |
| Gøtzsche & Johansen | −0.05 | −0.17 to 0.07 | 1115 | 0.39 | 0% |
Standardized mean differences as calculated by Gøtzsche and Johansen37 with a fixed‐effect model.
Risk ratios for the number of patients improved related to environmental strategy in the meta‐analysis by Gøtzsche and Johansen37
| Strategy | RR | 95% CI | Patients ( |
|
|
|---|---|---|---|---|---|
| Sojourn high altitude | NA | NA | NA | NA | NA |
| Total avoidance | NA | NA | NA | NA | NA |
| Exposure‐based | NA | NA | NA | NA | NA |
| Concurrent bedroom | 1.06 | 0.75‐1.50 | 282 | 0.82 | 0% |
| 1 barrier | 1.07 | 0.75‐1.53 | 233 | 0.77 | 0% |
| 2‐3 barriers | 0.85 | 0.19‐3.79 | 49 | 0.87 | 0% |
| Air purification | 0.67 | 0.24‐1.87 | 56 | 0.61 | 0% |
| Mixed strategies | 1.01 | 0.73‐1.40 | 338 | 0.96 | 0% |
| Gøtzsche & Johansen | 1.01 | 0.80‐1.27 | 338 | 0.94 | 0% |
Risk ratios as calculated by Gøtzsche and Johansen37 with a fixed‐effect model.